Patent · US Active

Fc containing polypeptides with altered glycosylation and reduced effector function

US9790268B2 · kind B2 · utility

20Cited by
31References
39Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 11, 2014
Grant dateOct 17, 2017
Priority date—
Expiry dateMar 24, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/73
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.